Home Healthcare Biotechnology Companion Diagnostics Market

Companion Diagnostics Market Size, Share & Trends Analysis Report By Technology (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), Immunohistochemistry, In Situ Hybridization, Others), By Indication (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Virology Diseases, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Companion Diagnostics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Polymerase Chain Reaction (PCR) 
    2. Next-generation Sequencing (NGS)
    3. Immunohistochemistry
    4. In Situ Hybridization
    5. Others
  2. Companion Diagnostics Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Autoimmune Diseases
    3. Cardiovascular Diseases
    4. Central Nervous System Disorders
    5. Virology Diseases
    6. Others
  3. Regional Companion Diagnostics Market
    1. North America
      1. North America Companion Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
      2. North America Companion Diagnostics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Cardiovascular Diseases
        4. Central Nervous System Disorders
        5. Virology Diseases
        6. Others
      3. U.S.
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      4. Canada
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
    2. Europe
      1. Europe Companion Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
      2. Europe Companion Diagnostics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Cardiovascular Diseases
        4. Central Nervous System Disorders
        5. Virology Diseases
        6. Others
      3. U.K.
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      4. Germany
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      5. France
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      6. Spain
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      7. Italy
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      8. Russia
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      9. Nordic
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      10. Benelux
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      11. Rest of Europe
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
    3. APAC
      1. APAC Companion Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
      2. APAC Companion Diagnostics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Cardiovascular Diseases
        4. Central Nervous System Disorders
        5. Virology Diseases
        6. Others
      3. China
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      4. Korea
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      5. Japan
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      6. India
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      7. Australia
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      8. Singapore
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      9. Taiwan
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      10. South East Asia
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      11. Rest of Asia-Pacific
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
    4. Middle East and Africa
      1. Middle East and Africa Companion Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
      2. Middle East and Africa Companion Diagnostics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Cardiovascular Diseases
        4. Central Nervous System Disorders
        5. Virology Diseases
        6. Others
      3. UAE
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      4. Turkey
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      5. Saudi Arabia
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      6. South Africa
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      7. Egypt
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      8. Nigeria
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      9. Rest of MEA
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
    5. LATAM
      1. LATAM Companion Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
      2. LATAM Companion Diagnostics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune Diseases
        3. Cardiovascular Diseases
        4. Central Nervous System Disorders
        5. Virology Diseases
        6. Others
      3. Brazil
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      4. Mexico
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      5. Argentina
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      6. Chile
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      7. Colombia
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
      8. Rest of LATAM
        1. Polymerase Chain Reaction (PCR) 
        2. Next-generation Sequencing (NGS)
        3. Immunohistochemistry
        4. In Situ Hybridization
        5. Others
        6. Oncology
        7. Autoimmune Diseases
        8. Cardiovascular Diseases
        9. Central Nervous System Disorders
        10. Virology Diseases
        11. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.